Evidence map›Paper›PMID 28450891›Full record

ArticleTherapeutic advances in neurological disorders2017

Adrenocorticotropic hormone

Regina Berkovich, Rohit Bakshi, Lilyana Amezcua, Robert C Axtell, Steven Y Cen, Shahamat Tauhid, Mohit Neema, Lawrence Steinman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in neurological disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Effects of Psychological Stress on Multiple SclerosisCNS & neurological disorders drug targets · 2024
    Review
  2. Insomnia in neurological diseases.Neurological research and practice · 2021
    Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Regina BerkovichUSC MS Comprehensive Care Center and Research Group, 1520 San Pablo Street, Suite 3000, Los Angeles, CA 90033, USA.
Rohit BakshiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lilyana AmezcuaUniversity of Southern California, Keck School of Medicine, Los Angeles, CA, USA.
Robert C AxtellOklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Steven Y CenUniversity of Southern California, Keck School of Medicine, Los Angeles, CA, USA.
Shahamat TauhidBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mohit NeemaBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lawrence SteinmanStanford University School of Medicine, Stanford, CA, USA.
Harvard University · USUniversity of Southern California · USBrigham and Women's Hospital · USLAC+USC Medical Center · USOklahoma Medical Research Foundation · USStanford University · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Robert Hal Scofield · 2013 to 2026
$68.2M
Functional Interaction Between T-cell and B-cell Immune Pathways in Neuro- inflammatory DisordersR56AI118787 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI AXTELL, ROBERT C, LESSARD, CHRISTOPHER J · 2016 to 2016
$646k
NIAID NIH HHS R56 AI118787NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

backgroundThe objective of this study was to evaluate monthly intramuscular adrenocorticotropic hormone (ACTH) gel

methodsThis was a prospective, open-label, examiner-blinded, 15-month pilot study evaluating patients with Expanded Disability Status Scale (EDSS) score 3.0-6.5 and at least one clinical relapse or new T2 or gadolinium-enhanced lesion in the previous year. Twenty-three patients were randomized to ACTH (

resultsRelapse rates differed significantly [ACTH 0.08, 95% confidence interval (CI) 0.01-0.54

conclusionsThis study provided class II evidence that ACTH produced better examiner-assessed cumulative rates of relapses per patient than IVMP in the adjunctive treatment of breakthrough disease in multiple sclerosis.

Indexed as

adrenocorticotropic hormonemethylprednisolonemultiple sclerosispsychiatric symptomsrelapse

Identifiers

PMID28450891
PMCPMC5400152
OpenAlexW2538142428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.